

## Daily evidence digest

23 March 2022

The daily evidence digest collates recently released reports and evidence – provision of these links does not imply endorsement nor recommendation.

### Comirnaty and Vaxzevria in people over 50, anticoagulation in patients with atrial fibrillation and COVID-19, surveillance systems for the new normal

#### Peer reviewed journals featured:

- Observational studies on:
  - Effectiveness of Comirnaty (Pfizer) and Vaxzevria (AstraZeneca) in people over 50 [here](#)
  - Combinatorial influence of environmental temperature, obesity and cholesterol on SARS-CoV-2 infectivity [here](#)
  - Mental health trajectory of UK university staff and students during COVID-19 [here](#)
- An editorial on anticoagulation in patients with atrial fibrillation and COVID-19 [here](#)
- Commentary on the impact from the UK's government removal of COVID-10 mitigations and testing [here](#)

#### Letters and correspondence discussed:

- COVID-19 surveillance systems for the new normal [here](#)

#### Pre-peer review articles featured:

- Cost-effectiveness of antigen testing for ending COVID-19 isolation [here](#)

#### News and blogs

- Sixty seconds on COVID toe [here](#)

[Click here](#) to subscribe to the daily evidence digest.

#### Living Evidence Tables

Living Evidence tables are up-to-date summaries of emerging evidence. Tables are available on SARS-CoV-2 [vaccines](#), and [variants](#) of concern, [post-acute sequelae of COVID-19 \(PASC\)](#), [surgery and COVID-19](#), [rapid testing](#) and [risk mitigation strategies](#).